Gesamtverzeichnis
-
1
Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.
Int J Clin Pharmacol Ther. 2012 Jan;50(1):24-32.
Conflicts of interest: RQ, AF, SF, KS, MS: This investigation of the DAPI - German Institute for Drug use Evaluation has been financially supported by Sanofi-Aventis Deutschland GmbH, Berlin, in the years 2008 and 2009. RQ: Results of this study have been presented at the 12th Annual European ISPOR-Congress in Paris (October 24 - 27, 2009), the 16th annual meeting of the Gesellschaft für Arzneimittelepidemiologie (GAA) e. V. in Berlin (November 19 - 20, 2009), and the 70th scientific sessions of the American Diabetes Association in Orlando (June 25 - 29, 2010). Registration fees and travel costs have been paid by Sanofi-Aventis Deutschland GmbH. MU, KL, WEM: None. FWD: Employee of Sanovi-Aventis Deutschland GmbH, Berlin.
-
1
Comparison of different ways of calculation (DDD vs. SPC) to determine persistence and compliance with beta blockers in the DAPI database.
Poster 10. Deutscher Kongress für Versorgungsforschung (DKVF) und 18. Jahrestagung der GAA. Köln, 20.-22.10.2011.
German Medical Science GMS Publishing House; 2011. Doc11dkvf039. Abstracts, S. 28
www.egms.de/static/en/meetings/dkvf2011/11dkvf039.shtml
Conflicts of interest: none declared.
-
1
Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.
J Hypertens. 2011 Sep;29(9):1837-45.
www.ncbi.nlm.nih.gov/pubmed/21738055
Conflicts of interest: none declared.
-
1
Association between generic substitution of valproate and therapeutic modification of antiepileptic therapy – a cohort study with time-dependent exposure utilizing the DAPI ambulatory drug claims data
Vortrag 56. Jahrestagung der GMDS und 6. Jahrestagung der DGEpi (Deutsche Gesellschaft für Epidemiologie). Mainz, 26.-29.09.2011.German Medical Science GMS Publishing House; 2011. Doc11gmds236.
www.egms.de/static/en/meetings/gmds2011/11gmds236.shtml
Conflicts of interest: none declared.
-
1
Strategien zur Verbesserung der Einnahmetreue von Medikamenten.
Dtsch Med Wochenschr. 2011 Aug;136(31-32):1616-21.
www.ncbi.nlm.nih.gov/pubmed/21809255
Conflicts of interest: none declared.
-
1
Verbesserung der Therapietreue bei Hypertonikern - eine Aufgabe für den Apotheker
PZ Prisma 2011; 18: 98-106.
www.govi.de/xtcommerce/product_info.php
Conflicts of interest: none declared.
-
1
Persistence under treatment with ramipril
European Society for Patient Adherence, Compliance and Persistence (ESPACOMP) symposium, 05.09.2008, Basel, Switzerland.
Espacomp 2008 Basel Abstract Ude
Conflicts of interest: none declared.
-
1
Impact of rebate contract legislation on generic substitution of valproate – a retrospective study of ambulatory drug dispensing in the DAPI database
17. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA), 25.-26.11.2010, Osnabrück, Germany.
www.egms.de/static/de/meetings/gaa2010/10gaa08.shtml
Conflicts of interest: The DAPI received financial support for this study from Desitin; Kuhn K. employee Desitin.
-
1
Effect of generic switch on pharmacy refill compliance after ramipril patent expiry – a retrospective study using the DAPI database
17. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA), 25.-26.11.2010, Osnabrück, Germany.
www.egms.de/static/de/meetings/gaa2010/10gaa36.shtml
Conflicts of interest: none declared.
-
1
Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib
26th ICPE - International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment, 19.-22. August 2010, Brighton, England, UK: Pharmacoepi and Drug Safety 2010 Vol. 19 Suppl. 1 p. S 259 (Abstract number 611).
Conflicts of interest: RQ, AF, SF, KS, MS: This investigation of the DAPI - German Institute for Drug use Evaluation has been financially supported by Sanofi-Aventis Deutschland GmbH, Berlin, in the years 2008 and 2009. RQ: Results of this study have been presented at the 12th Annual European ISPOR-Congress in Paris (October 24 - 27, 2009), the 16th annual meeting of the Gesellschaft für Arzneimittelepidemiologie (GAA) e. V. in Berlin (November 19 - 20, 2009), and the 70th scientific sessions of the American Diabetes Association in Orlando (June 25 - 29, 2010). Registration fees and travel costs have been paid by Sanofi-Aventis Deutschland GmbH. MU, KL, WEM: None. FWD: Employee of Sanovi-Aventis Deutschland GmbH, Berlin.
Hinweis: Für die Ansicht der PDF Dokumente wird der Acrobat Reader benötigt. Klicken Sie auf die Grafik, um ihn herunterzuladen.
